We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Catalyst Sues FDA Over $375,000 Rare Disease Treatment

Catalyst Sues FDA Over $375,000 Rare Disease Treatment

June 19, 2019

A Florida drug company at the heart of ongoing disputes over the price of life-saving drugs has doubled down, bringing a federal lawsuit against the FDA for the agency’s alleged end-run around the drug company’s commercial rights.

In a complaint filed in the federal court for the Southern District of Florida, Catalyst Pharmaceuticals says that the FDA had no right to award pediatric rights for Ruzurgi (amifampridine) to Jacobus Pharmaceuticals to treat Lambert-Eaton Myasthenic Syndrome, a rare, genetic disorder in which a patient’s autoimmune system attacks his or her own tissues.

Catalyst had won orphan status for its version of amifampridine, which it called Firdapse. But when it listed Firdapse’s price at $375,000 per year—previous versions had cost between $300 and $500 per month—it drew condemnation from patient advocates and political leaders, including Sen. Bernie Sanders (I-Vt.).

Firdapse won approval for treatment of adults with Lambert-Eaton and more than one commenter saw the FDA’s pediatric approval for Jacobus—a nonprofit group—as a way to diffuse the controversy by giving doctors a cheaper, off-label alternative.

View today's stories

Drugs Regulatory Affairs

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Expert Says FDA Under No Obligation to Educate Companies on Inspection Rights

    • FDA Deems Hamilton Ventilator Recall Class I for Software Issue Causing Device to Stop

    • Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

    • FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing